Phathom Pharmaceuticals, Inc. (PHAT) Stock Analysis

Company Overview

Phathom Pharmaceuticals, Inc. (PHAT) is capitalised at $768.56M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 371.

PHAT last closed at $9.50 on September 4, 2026. That is +$0.45 (+4.97%) against the previous close. Over the past 52 weeks the price has ranged from $8.21 to $18.31. The latest close sits 15.71% above that 52-week low.

Financial Health

In fiscal 2025, Phathom Pharmaceuticals, Inc. reported revenue of $175.11M. That is +216.93% against the prior fiscal year, when revenue was $55.25M. The same year closed with a net loss of $221.25M. Profit margin runs at −41.34%. That is 41.3 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −1.31.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $175.11M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 8.56. The price-to-sales ratio is 3.21. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −20.83%. Across 5 years the annualized return works out at −23.40%. Beta against the wider market is reported at 0.51. Daily returns over the trailing 6 years annualize to a volatility of 88.56%.

Growth & Income

The record shows no dividend for PHAT.

So far in 2026 the price is −42.74%. The strongest complete calendar year on file is 2025 at +104.31%; the weakest is 2022 at −42.96%. Of the 6 complete calendar years on file, 2 finished higher.